TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34937189
Drug: Piperacillin-Tazobactam intermittent
Normalized name: piperacillin / tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-Tazobactam intermittent bolus, extended infusion, and continuous infusion methods
Study: 34937720
Drug: Stratified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratified treatment based on prognostic factors
Study: 34938285
Drug: AS03-adjuvanted H1N1pdm09
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted H1N1pdm09 vaccine (2009)
Study: 34938664
Drug: Venetoclax 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax 800 mg/day
Study: 34939008
Drug: HDx therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDx therapy (medium cut-off dialyzer) for 12 weeks after a 2-week baseline observation period of conventional high-flux HD
Study: 34939008
Drug: HDx therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDx therapy
Study: 34939013
Drug: Marine n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine n-3 PUFA (2.6 g daily for 44 weeks)
Study: 34939444
Drug: Yoga practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga practice combined with patient education (PE) for at-home practice, 12 weeks duration, including two 6-week periods: P1 with one 90-minutes supervised yoga-PE session/week and 15-minutes daily at-home yoga, P2 with daily autonomous at-home yoga sessions.
Study: 34939987
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy initiation among AYALWH older than 10 years
Study: 34941047
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with anlotinib, irinotecan, and vincristine
Study: 34941067
Drug: Leuprorelin 1.88
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprorelin 1.88 to 3.75 mg subcutaneously once every 4 weeks for 96 weeks
Study: 34941996
Drug: Glofitamab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glofitamab (5 µg-25 mg) after single-dose obinutuzumab pretreatment (1000 mg) 7 days prior
Study: 34941996
Drug: Glofitamab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glofitamab (5 µg-25 mg)
Study: 34942138
Drug: Lower-sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lower-sodium oxybate (2.5-9.0 g/night)
Study: 34944886
Drug: Yeast-derived beta
Normalized name: yeast, beta-D-glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast-derived beta glucan (BG) combined with anti-GD2 murine monoclonal antibody 3F8, intravenous 3F8 at a fixed dose of 10 mg/m².
Study: 34945816
Drug: Pharmacogenomically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenomically guided medication treatment
Study: 34945816
Drug: Standard medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medication treatment
Study: 34950101
Drug: Drug-Induced Sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Induced Sleep Endoscopy
Study: 35121899
Drug: BNT162b2 or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 or AZD1222 vaccines (two doses, administered 12 weeks apart)
Study: 35121899
Drug: BNT162b2 or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 or AZD1222 vaccines
Study: 34950880
Drug: anti-CD20 treatment
Normalized name: Allogeneic anti-CD20 CAR T cells
DrugBank: PBCAR20A (DB17189)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-CD20 treatment
Study: 34951594
Drug: Daily incentives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily incentives for self-weighing (loss incentive)
Study: 34952881
Drug: Melatonin 4
Normalized name: vit B/folic acid/calcium/soy xt/black cohosh xt/melatonin 400 mcg-125 mg-62 mg-40 mg (day)/175 mg-62 mg-1 mg (night) ORAL CAPSULE, SEQUENTIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 4 mg per os, every night from anaesthesiologist preoperative consultation up to 5 days after surgery.
Study: 34953337
Drug: Perampanel as
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel as an add-on therapy
Study: 34953600
Drug: Stereotactic ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic ablative body radiotherapy (SABR) followed by pembrolizumab 200 mg administered Q3W for eight cycles
Study: 34953624
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg daily and tremelimumab at 3 mg/kg IV Q4W for 6 cycles followed by Q12W until progression or unacceptable toxicity.
Study: 34953624
Drug: Tremelimumab at
Normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab at 6 mg/kg IV Q4W for 6 cycles followed by Q12W until progression or unacceptable toxicity.
Study: 34953624
Drug: Tremelimumab at
Normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab at 10 mg/kg IV Q4W for 6 cycles followed by Q12W until progression or unacceptable toxicity.
Study: 34953816
Drug: Anakinra (2-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (2-11 mg/kg/day)
Study: 34953816
Drug: Anakinra (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (IV dosing every 8-12 hours)
Study: 34953816
Drug: Anakinra (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (IV therapy during hospitalization)
Study: 34954052
Drug: SY-007 (1-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY-007 (1-60 mg)
Study: 34954052
Drug: SY-007 (10-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY-007 (10-30 mg)
Study: 34954341
Drug: Empiric second-line
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric second-line treatment (triple therapy with amoxicillin and levofloxacin)
Study: 34954341
Drug: Moxifloxacin-containing triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin-containing triple therapy or levofloxacin-containing quadruple therapy (with bismuth)
Study: 34954341
Drug: 14-day regimens
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14-day regimens using high doses of proton pump inhibitors with levofloxacin or moxifloxacin
Study: 34954341
Drug: 3-in-1 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-in-1 single capsule or levofloxacin-bismuth quadruple therapy
Study: 34954341
Drug: 14-day quinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day quinolone triple therapies, 14-day levofloxacin-bismuth quadruple therapy, 14-day tetracycline-bismuth classic quadruple therapy, and 10-day bismuth quadruple therapy (as a single capsule)
Study: 34955443
Drug: Lenalidomide (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (35 mg) administered for 28 days
Study: 34956230
Drug: Histamine dihydrochloride
Normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histamine dihydrochloride and low-dose IL-2 (HDC/IL-2)
Study: 34956230
Drug: G allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: G allele of rs1049174
Study: 34957480
Drug: Modified plasmid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified plasmid for selection without antibiotic resistance
Study: 34957654
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide 3 mg once daily for 5 days, followed by 7 mg for 5 days
Study: 34958928
Drug: Lazertinib 240
Normalized name: lazertinib 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazertinib 240 mg
Study: 34959982
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral vitamin D supplementation (100,000 IU 25-OH VD every 3 weeks from day 1 of cycle 1 to day 1 of cycle 5)
Study: 34959982
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral vitamin D supplementation
Study: 34961476
Drug: High hs-CRP
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High hs-CRP levels (> 3 mg/L)
Study: 34961476
Drug: High hs-CRP
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High hs-CRP levels (> 3 mg/L) and hypoalbuminemia
Study: 34961547
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 mg daily for 14 weeks)
Study: 34961567
Drug: Optimized standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized standard of care (control) including billboards/posters, radio shows, healthcare worker training, one-stop adolescent and youth-friendly services, information/motivation walls, pill containers, and tools for HCW during clinical visits.
Study: 34961659
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose rate brachytherapy or stereotactic body radiotherapy
Study: 34961659
Drug: Single-fraction high
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-fraction high dose rate brachytherapy
Study: 35857060
Drug: Second-line treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line treatment for T2DM
Study: 34963486
Drug: hf-tRNS (100-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: hf-tRNS (100-500 Hz) delivered for 20 min with a current intensity of 2 mA and a 1-mA offset twice a day on 5 consecutive weekdays
Study: 34965890
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral selinexor with different standard chemotherapies
Study: 34965951
Drug: Trabectedin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin at 1.2 mg/m2 combined with durvalumab 1,120 mg every 3 weeks in STS cohort
Study: 34965951
Drug: Trabectedin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin at 1.2 mg/m2 combined with durvalumab 1,120 mg every 3 weeks in ovarian carcinoma cohort
Study: 34966667
Drug: Home-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based physical activity program during neoadjuvant chemotherapy (NACT) combining aerobic and strengthening exercises.
Study: 34966798
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo or standard treatment not specified)
Study: 34967751
Drug: Tablet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based cognitive battery (Adaptive Cognitive Evaluation [ACE])
Study: 34967751
Drug: Tablet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based cognitive battery (ACE)
Study: 34967916
Drug: Ixekizumab 80
Normalized name: ixekizumab 80 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab 80 mg Q2W from Week 12 to Week 20
Study: 34968102
Drug: Specific instrumental
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific instrumental activities of daily living (IADL) training (one intervention)
Study: 34968106
Drug: varenicline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: varenicline (1 mg/bid)
Study: 34968106
Drug: varenicline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: varenicline (1 mg/bid) plus naltrexone (50 mg/day)
Study: 34969664
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy for insomnia (CBT-I), 5 sessions, gold-standard treatment.
Study: 34969664
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy for insomnia (CBT-I)
Study: 34969665
Drug: Indigo naturalis
Normalized name: indigo
DrugBank: Indigo (DB16862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indigo naturalis (IN) 500 mg/day or 1.5 g/day for 8 weeks
Study: 34970744
Drug: Free epithelialized
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free epithelialized gingival/mucosal grafts (FEGs) used for KT augmentation
Study: 34970774
Drug: Intravenous voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous voriconazole therapy
Study: 34971971
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (Zol) in conjunction with radiation therapy (RT)
Study: 34972609
Drug: Volume challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume challenge (200 ml saline in 20 s)
Study: 34973077
Drug: Tofacitinib 5→10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5→10 mg BID (Dose-up)
Study: 34973077
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg BID (Stay-on 5)
Study: 34973077
Drug: Tofacitinib 10→5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10→5 mg BID (Dose-down)
Study: 34973077
Drug: Tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10 mg BID (Stay-on 10)
Study: 34973601
Drug: Racemic ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic ketamine treatment
Study: 34974453
Drug: Homologous third
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homologous third dose of inactivated whole-virion vaccine
Study: 34974510
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (2 mg) with a treat-and-extend regimen
Study: 34975844
Drug: Allogeneic Vγ9Vδ2
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic Vγ9Vδ2 T-cell therapy adjunct with anti-TB drugs
Study: 34976830
Drug: AdHER2 DC
Approvals — FDA: no, EMA: no, PMDA: no
Description: AdHER2 DC vaccine
Study: 34977109
Drug: Oral Nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Nutritional Supplementation
Study: 34977512
Drug: Fresh lemon
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL SPRAY [PH5B Disinfectant Fresh Lemon]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh lemon juice supplementation (60 mL twice daily)
Study: 34977602
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of SARS-CoV-2 vaccines
Study: 34977602
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of SARS-CoV-2 vaccines
Study: 34977602
Drug: Healthy controls
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy controls receiving two doses of SARS-CoV-2 vaccines
Study: 34977972
Drug: Erdafitinib 6-mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdafitinib 6-mg/day
Study: 34977972
Drug: Erdafitinib 8-mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdafitinib 8-mg/day
Study: 34977972
Drug: Erdafitinib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdafitinib (both doses)
Study: 34978890
Drug: Monthly long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly long-acting cabotegravir + rilpivirine
Study: 34978890
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dolutegravir/abacavir/lamivudine
Study: 34978890
Drug: Long-acting therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting therapy
Study: 34979020
Drug: Blinatumomab (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab (up to 5 cycles, continuous infusion, cycle: 4 weeks on/2 weeks off)
Study: 34979970
Drug: PDI drugs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PDI drugs (e.g., Zolpidem, Zopiclone, Bromazepam, Tramadol, Pregabalin)
Study: 34979970
Drug: PDI drugs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PDI drugs
Study: 34980038
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with three cycles of carboplatin and paclitaxel
Study: 34980038
Drug: Regular dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dose arm (chemoradiation to 70 Gy with concurrent cisplatin)
Study: 34980176
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of an adenovirus targeting SNHG15
Study: 34980208
Drug: Personalized daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized daily text messaging (SMS/MMS), posts on social media platforms, and online groups
Study: 34980208
Drug: Personalized daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized daily text messaging (SMS/MMS), posts on social media platforms, online groups, and brief technology-mediated health coaching
Study: 34980220
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular progesterone 40 mg per day from D3 to 8 weeks of gestation if clinical pregnancy is achieved.
Study: 34980224
Drug: Hydrocortisone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (50 mg intravenous bolus every 6 hours) and fludrocortisone (50 μg once a day enterally) for 7 days or until discharge from the ICU
Study: 34980502
Drug: SSTR2-targeted peptide-radionuclide
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSTR2-targeted peptide-radionuclide receptor therapy (PRRT)
Study: 34980541
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus trastuzumab (arms B&C)
Study: 34980597
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg every 2 weeks + cabozantinib 40 mg every day
Study: 34980597
Drug: Nivolumab 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 480 mg every 4 weeks + cabozantinib 40 mg every day
Study: 34980633
Drug: Point-of-care C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point-of-care C reactive protein (POC CRP) testing, prescription guidance, and safety-netting advice.
Study: 34980909
Drug: Lentiviral globin
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentiviral globin gene therapy with reduced-intensity conditioning
Study: 34981077
Drug: Bamlanivimab 7000
Normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bamlanivimab 7000 mg and 700 mg
Study: 34981142
Drug: CC-90002 (anti-CD47
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-90002 (anti-CD47 monoclonal antibody) administered in escalating doses of 0.1-4.0 mg/kg
Study: 34981144
Drug: Deferiprone (DFP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferiprone (DFP), single 1500 mg dose
Study: 34981300
Drug: Hypofractionated stereotactic
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated stereotactic radiotherapy (HSRT) with doses of either 27.5 or 30 Gy
Study: 34981464
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CBT) for 16 sessions
Study: 34983430
Drug: Procalcitonin (PCT)
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin (PCT) with cutoff of 0.5 ng/mL
Study: 34983430
Drug: PCT for
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT for predicting sepsis-3 with cutoff of 0.5 ng/mL
Study: 34983600
Drug: Early, biomarker-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early, biomarker-guided steroid dosing
Study: 34983671
Drug: First Phase
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First Phase Insulin Response (FPIR) in IvGTT
Study: 34983751
Drug: Protein supplementation
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplementation of ≥1.5 g/kg/day in addition to standard nutrition for 7 days or until PICU discharge.
Study: 34983758
Drug: Cessation programme
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cessation programme with 3-monthly visits
Study: 34984540
Drug: Sugemalimab (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugemalimab (1200 mg fixed dose once every 3 weeks)
Study: 34984540
Drug: Sugemalimab (monotherapy)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Sugemalimab (DB16641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugemalimab (monotherapy)
Study: 34984540
Drug: Sugemalimab (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugemalimab (in combination with SOC chemotherapy)
Study: 34987618
Drug: Dendritic cell
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cell vaccines (DCV) plus neoadjuvant chemotherapy (NAC)
Study: 34987618
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) alone
Study: 34988132
Drug: Oral Water
Normalized name: Oral Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Water
Study: 34988480
Drug: Chemoradiation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation treatment for esophageal cancer
Study: 34988780
Drug: DiffCORE MR
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DiffCORE MR formulations (240 mg) administered in fasted and fed states
Study: 34988780
Drug: DiffCORE MR-16
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DiffCORE MR-16 h formulation (120-960 mg)
Study: 34988917
Drug: Treatment intensification
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment intensification (addition of new insulin, increase in insulin dosage, increase in insulin injection frequency, addition of non-insulin antihyperglycemic agents)